National Pension Service Sells 1,810 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

National Pension Service lowered its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 367,737 shares of the medical equipment provider’s stock after selling 1,810 shares during the quarter. National Pension Service owned 0.18% of Zimmer Biomet worth $38,844,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of ZBH. Equity Investment Corp acquired a new position in shares of Zimmer Biomet in the 3rd quarter worth approximately $70,104,000. Hotchkis & Wiley Capital Management LLC raised its holdings in shares of Zimmer Biomet by 49.1% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider’s stock worth $189,161,000 after buying an additional 577,320 shares in the last quarter. Van ECK Associates Corp raised its holdings in shares of Zimmer Biomet by 12.4% in the 3rd quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock worth $391,239,000 after buying an additional 411,163 shares in the last quarter. Thompson Siegel & Walmsley LLC acquired a new position in shares of Zimmer Biomet in the 3rd quarter worth approximately $41,588,000. Finally, FMR LLC raised its holdings in shares of Zimmer Biomet by 27.6% in the 3rd quarter. FMR LLC now owns 750,336 shares of the medical equipment provider’s stock worth $80,999,000 after buying an additional 162,384 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on ZBH shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a report on Friday, February 7th. Raymond James dropped their price target on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Truist Financial reaffirmed a “hold” rating and set a $113.00 price target (down from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. JMP Securities reaffirmed a “market outperform” rating and set a $140.00 price target on shares of Zimmer Biomet in a report on Friday, February 7th. Finally, Barclays dropped their price target on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a report on Monday, February 10th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $124.15.

Zimmer Biomet Trading Up 0.3 %

Shares of NYSE:ZBH opened at $104.32 on Friday. Zimmer Biomet Holdings, Inc. has a 12-month low of $97.69 and a 12-month high of $133.90. The stock has a market cap of $20.77 billion, a PE ratio of 23.44, a P/E/G ratio of 1.95 and a beta of 1.02. The business has a 50 day moving average of $105.72 and a 200-day moving average of $107.38. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the previous year, the firm earned $2.20 earnings per share. As a group, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.92%. The ex-dividend date is Monday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is currently 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.